1. Home
  2. LLYVK vs CYTK Comparison

LLYVK vs CYTK Comparison

Compare LLYVK & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LLYVK

Liberty Media Corporation

HOLD

Current Price

$94.12

Market Cap

8.6B

Sector

Industrials

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$65.73

Market Cap

7.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LLYVK
CYTK
Founded
1991
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.6B
7.6B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
LLYVK
CYTK
Price
$94.12
$65.73
Analyst Decision
Strong Buy
Analyst Count
0
19
Target Price
N/A
$89.26
AVG Volume (30 Days)
254.9K
1.5M
Earning Date
02-27-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$13,368,000.00
Revenue This Year
N/A
$7.37
Revenue Next Year
$5.71
$310.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$69.47
$29.31
52 Week High
$102.14
$70.98

Technical Indicators

Market Signals
Indicator
LLYVK
CYTK
Relative Strength Index (RSI) 46.32 53.92
Support Level $79.40 $59.12
Resistance Level $94.46 $67.93
Average True Range (ATR) 3.31 2.02
MACD -0.44 0.06
Stochastic Oscillator 14.86 37.33

Price Performance

Historical Comparison
LLYVK
CYTK

About LLYVK Liberty Media Corporation

Liberty Live Holdings Inc focuses on live entertainment investments. The company maintains a substantial ownership position in Live Nation Entertainment, the primary international promoter of concerts, events, and ticketing through platforms like Ticketmaster, alongside sponsorship and hospitality services via QuintEvents.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: